XNAS
ATTO
Market cap952mUSD
Sep 18, Last price
22.14USD
1D
-2.60%
IPO
8.64%
Name
Attovia Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1m
Net income
-61m
CFO
-59m
Dividend
Nov 09, 20170.3384 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Key people
Fu Tao
Chief Executive Officer, Founder
David Bellovin
Co-Founder, Vice President - Discovery and Translational Biology
Zhan Hangjun
Co-Founder, Chief Technology Officer
Zaneta Odrowaz
Co-Founder, Chief Business Officer
Petter Veiby
Co-Founder, Chief Scientific Officer
Steven Chan
Chief Financial Officer · since 2024
Valuation
Title in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT |